CoChat
Sign Up
Cited by 343Dermatology and Skin DiseasesAsthma and respiratory diseasesPsoriasis: Treatment and Pathogenesis

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Dupilumab: A review of its use in the treatment of atopic dermatitis

Gooderham, Melinda J., Hong, H. Chih-ho, Eshtiaghi, Panteha, Papp, Kim A.·2018·Journal of the American Academy of Dermatology
DOI 10.1016/j.jaad.2017.12.022
Open this paper in CoChat — free account

Abstract

Atopic dermatitis (AD) is a chronic, pruritic immune-mediated inflammatory dermatosis characterized by a T helper 2 (Th2) immune response phenotype and may be associated with systemic inflammation. Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist that inhibits IL-4 and IL-13 signaling through blockade of the shared IL-4α subunit. Blockade of IL-4/13 is effective in reducing Th2 response. Dupilumab has recently been approved in the United States and Europe for the treatment of adult patients with moderate-to-severe AD. Clinical trials have shown that adults with moderate-to-severe AD who receive weekly or biweekly dupilumab injections have significantly improved clinical and patient-reported outcomes, including Eczema Area Severity Index, SCORing Atopic Dermatitis, Dermatology Life Quality Index, and itch Numeric Rating Scale scores. Concomitant use of topical corticosteroids along with dupilumab results in a greater improvement in signs and symptoms of AD than with use of dupilumab alone. Biomarker analyses show that dupilumab modulates the AD molecular signature and other Th2-associated biomarkers. Common adverse events reported in the clinical trials were nasopharyngitis, upper respiratory tract infection, injection site reactions, skin infections, and conjunctivitis. These were mild-to-moderate in nature, and overall rates of adverse events occurred with similar frequency between the treatment and placebo groups. There were no significant serious safety concerns identified in phase III clinical trials. Dupilumab, as monotherapy or with concomitant use of topical corticosteroids, can significantly improve clinical outcomes and quality of life in patients suffering from moderate-to-severe AD. Ongoing studies of dupilumab will help determine the clinical efficacy and safety profile of its long-term use.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jaad.2017.12.022

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 17 references

Cited by

Sorted by citations

Items 301–341 of 341

Related

See all

Metadata

Authors
Gooderham, M. J., Hong, H. C.-H., Eshtiaghi, P., & Papp, K. A.
Affiliations
  • Queen's University (CA)
  • University of British Columbia (CA)
  • Probity Medical Research (CA)
Corresponding author
Gooderham, Melinda J.
ORCID
Venue
Journal of the American Academy of Dermatology
Publisher
Elsevier BV
Published
2018-03
Volume
78
Issue
3
Pages
S28-S36
ISSN
0190-9622 (ISSN-L)
DOI
10.1016/j.jaad.2017.12.022
OpenAlex
W2789024274
Cited by
343
References
17
Citations by year
2026: 30 · 2025: 39 · 2024: 40 · 2023: 41 · 2022: 47 · 2021: 64 · 2020: 43 · 2019: 28 · 2018: 10
FWCI
39.26
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Journal of the American Academy of Dermatology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bayer
  • LEO Pharma
  • Sanofi
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords
dupilumab, atopic dermatitis, IL-4 receptor alpha antagonist, IL-4/IL-13 signaling, Th2 immune response, topical corticosteroids, biomarkers, adverse events, quality of life, moderate-to-severe atopic dermatitis
MeSH terms
Patient Reported Outcome Measures, Antibodies, Monoclonal, Biological Products, Dermatitis, Atopic, Female, Humans, Male, Quality of Life, Severity of Illness Index, Drug Delivery Systems, Treatment Outcome, Clinical Trials, Phase III as Topic, Risk Assessment, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review